# A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT06066125** · PHASE3 · COMPLETED · sponsor: **Akeso** · enrollment: 351 (actual)

## Conditions studied

- Psoriasis
- Skin Diseases

## Interventions

- **DRUG:** AK111
- **DRUG:** AK111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06066125
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-31
- **Primary completion:** 2024-08-19
- **Final completion:** 2024-08-19
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066125, "A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06066125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*